Ivabradin Ratiopharm

Ivabradine, the active ingredient in Ivabradin Ratiopharm, is an If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used in chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradin Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is indicated for cardiovascular conditions where heart‑rate reduction is beneficial.

Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate. Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalisation by decreasing heart rate. Elevated resting heart rate: helps achieve target heart rate when beta‑blockers are unsuitable.

Ivabradine may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below prescribed target. - Headache. - Dizziness.

Serious or Rare Side Effects: - Symptomatic bradycardia leading to syncope. - Atrial fibrillation. - Severe hypotension or heart block.

When prescribing Ivabradine, clinicians should consider several safety precautions. - Cardiovascular assessment: evaluate baseline heart rate and rhythm before initiation. - Monitoring: check heart rate regularly after starting therapy and after dose adjustments. - Contraindications: avoid use in patients with severe hepatic impairment. - Concomitant medications: use caution with other heart‑rate lowering agents (e.g., beta‑blockers, calcium channel blockers). - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivabradine interacts with several medicines that can alter its plasma concentration or additive heart‑rate effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole): may increase ivabradine levels and cause excessive bradycardia. - Other heart‑rate lowering agents (beta‑blockers, diltiazem, verapamil, digoxin): risk of severe bradycardia. - Concomitant use with other If channel inhibitors: additive effect on sinoatrial node.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - Diuretics causing electrolyte imbalance: can predispose to arrhythmias. - Antihypertensive agents (ACE inhibitors, ARBs): monitor blood pressure and heart rate.